Key details: data acquisition of studies used for analysis
| Study | Plasma Aβ40 levels | Plasma Aβ42 levels | Plasma Aβ42/Aβ40 ratio | Other Aβ measures | Method | PET tracer |
| Chatterjee et al 201936 | PET (−)=307.44±54.16, PET (+)=332.82±73.71 | PET (−)=16.01±3.74, PET (+)=15.71±3.48 | PET (−)=0.052±0.008, PET (+)=0.047±0.005 | Not available | ELISA | FBB |
| Doecke et al 202017 | Not available | Not available | PET (−)=0.092±0.027, PET (+)=0.075±0.02 (18 m) | Not available | ELISA | PiB |
| Kaneko et al 201437 | Not available | PET (−)=0.21±0.072, PET (+)=0.14±0.065, PET (+) (CN)=0.14±0.051 | PET (−)=0.011±0.005, PET (+)=0.007±0.003, PET (+) (CN)=0.007±0.003 | Not available | IP-MS | PiB |
| Li 2019 | PET (−)=219.14±116.15, PET (+)=221.76±109.53 | PET (−)=10.91±5.44, PET (+)=9.01±4.87 | PET (−)=0.0566±0.0231, PET (+)=0.0425±0.0203 | Not available | Simoa | PiB |
| Lin 201938 | PET (−)=49.1±7.3, PET (+)=50.9±7.7 | PET (−)=17.6±3.3, PET (+)=16.3±2.3 | PET (−)=0.374±0.117, PET (+)=0.334±0.109 | Not available | IMR | AV45 |
| Nakamura et al 201839 | PET (−)=8.733±2.044, PET(+)=8.280±1.820 | PET (−)=0.379±0.095, PET (+)=0.291±0.067 | PET (−)=0.044±0.006, PET (+)=0.035±0.004 | PET(-)=23.373±3.313, PET(+)=28.729±3.060 (Aβ40/Aβ42 ratio) | IP–MS | PiB, FLUTE, AV45 |
| Palmqvist et al 201940 | PET (−)=485±71, PET (+)=483±73 | PET (−)=32.7±4.7, PET (+)=29.9±4.7 | PET (−)=0.0680±0.0077, PET (+)=0.0622±0.0078 | Not available | ELISA | FLUTE |
| Park 201741 | PET (−)=118.70±2.09, PET (+)=136.60±3.37 | Not available | PET (−)=0.36±0.01, PET (+)=0.30± 0.01 | Not available | xMAP | PiB |
| Pérez-Grijalba et al 42 2019 | Not available | Not available | PET (−)=0.1329 ±0.0208, PET (+)=0.0997±0.0197 | Not available | ELISA | PiB |
| Schindler et al 201943 | Not available | Not available | PET (−)=0.128±0.009, PET (+)=0.115±0.006 | Not available | IP–MS | PiB, AV45 |
| Vergallo 201934 | PET (−)=301.9± 87.8, PET (+)=295.5±75.4 | PET (−)=18.4±5.8; PET (+)=15.1±4.0 | Not available | PET (−)=16.7±5.2, PET (+)=19.4±3.3 (Aβ40:Aβ42 ratio) | ELISA | AV45 |
| Wang et al 20208 | PET (−)=48.57±7.71, PET (+)=51.84±6.75 | Not available | Not available | Not available | IMR | AV45 |
| Verberk et al 202044 | PET (−)=165±30, PET (+)=157±28 | PET (−)=27±6, PET(+)=23±6 | PET (−)=0.17±0.03, PET (+)=0.14±0.03 | Not available | Simoa | FBB, PiB, FLUTE |
| West et al 202145 | PET (−)=440.435±81.870, PET (+)=452.325±103.933 | PET (−)=44.477±8.637, PET (+)=40.421±9.698 | PET (−)=0.101±0.010, PET (+)=0.090±0.010 | Not available | LC-MS/MS | PiB, FBB, AV45 |
| Tosun et al 202110 | Not available | Not available | PET (−)=0.12±0.01, PET (+)=0.11±0.01 (CU); PET (−)=0.13±0.01, PET (+)=0.11±0.009 (CI) | Not available | IP–MS | AV45 |
| Pyun et al 202135 | Not available | Not available | Not available | PET (−)=0.67±0.21, PET (+)=0.89±0.17 (OAβ) | ELISA | FBB, AV45, FLUTE |
AV45, 18F-florbetapir; Aβ, amyloid-β; ELISA, enzyme linked immunosorbent assay; FBB, 18F-florbetaben; FLUTE, 18F-flutemetamol; IMR, immunomagnetic reduction; IP-MS, immunoprecipitation-mass spectrometry; LC-MS/MS, high-throughput, liquid chromatography–tandem mass spectrometry; OAβ, Aβ oligomerisation; PET (+), amyloid-β positron emission tomography-positive; PET (−), amyloid-β positron emission tomography-negative; PiB, [11C] Pittsburgh compound B; Simoa, single-molecule array; xMAP, flexible multi-analyte profiling.